ARUP Laboratories Influenza A (H5) Virus by Qualitative NAAT
ARUP Laboratories has launched the laboratory-developed qualitative nucleic acid amplification test (NAAT) for the detection and subtyping of influenza A (H5) virus. Developed in collaboration with the US Centers for Disease Control and Prevention, the assay is intended to aid in the evaluation of individuals who may have been exposed to highly pathogenic avian influenza A virus, also known as H5N1 or bird flu. Sample collection is performed via a respiratory or conjunctival swab, which is then placed in viral transport media (also available through ARUP) and sent to ARUP Labs, a national reference laboratory and nonprofit enterprise of the University of Utah and its Department of Pathology.
Laboratory Corporation of America: H5 Bird Flu Test
Laboratory Corporation of America has launched an H5 bird flu molecular test to aid diagnosis of H5 bird flu infections in humans. The test, which was developed with support from the US Centers for Disease Control and Prevention, is available in the US (currently excluding New York state) for physicians to order for patients suspected of infection with the H5N1 virus. Patient nasopharyngeal swab samples can be collected at the point of care, placed in universal or viral transport media, and submitted to Labcorp for analysis via PCR.
Thermo Fisher Scientific Applied Biosystems MagMax Sequential DNA/RNA Kit
Thermo Fisher Scientific has launched the Applied Biosystems MagMax Sequential DNA/RNA Kit, a magnetic bead-based technology that promises to enable the sequential purification of high-quality genomic DNA and total RNA from a single whole blood or bone marrow sample for cancer research. The kit combines DNA and RNA isolation chemistries into a single kit, accommodating up to 15,000 white blood cells per microliter without the need for an additional red blood cell lysis step, according to the company. Compatible with the KingFisher Duo Prime, KingFisher Flex, and KingFisher Apex purification systems, the total turnaround time for the MagMax Sequential workflow is about 2.5 hours with a total hands-on time of roughly 45 minutes, Thermo Fisher said.
PGxAI Sirius
PGxAI has launched Sirius, an AI model for personalizing drug selection, dosage adjustment, and drug-drug interaction management based on a patient's genome. The model currently covers 730 drugs and 40 genes involved in drug metabolism, with plans to expand to 1,700 drugs. It is designed for use by hospital systems, diagnostic labs, and contract research organizations. PGxAI said it plans to expand the platform to cover all known and potential therapeutic substances and to integrate data from more than 1 billion health outcomes by 2030.
For more recently launched products and services, please visit the New Products page on our website.